このページの翻訳は実験的なもので、現在開発中です。お待ちしております

STRATA Skin Sciences 将来の成長

Future 基準チェック /06

STRATA Skin Sciencesは、35.5%と2.6%でそれぞれ年率35.5%で利益と収益が成長すると予測される一方、EPSはgrowで38.9%年率。

主要情報

39.7%

収益成長率

47.8%

EPS成長率

Medical Equipment 収益成長	17.6%
収益成長率	7.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	19 Aug 2024

今後の成長に関する最新情報

Recent updates

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Aug 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

Aug 07

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Jun 07

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 09

Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

Nov 24

STRATA Skin Sciences EPS in-line, beats on revenue

Nov 10

業績と収益の成長予測

NasdaqCM:SSKN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	40	-2	N/A	7	1
12/31/2025	34	-6	N/A	3	2
12/31/2024	33	-7	N/A	0	1
6/30/2024	33	-8	-3	-1	N/A
3/31/2024	33	-11	-4	-1	N/A
12/31/2023	33	-11	-6	-1	N/A
9/30/2023	35	-7	-6	-1	N/A
6/30/2023	36	-7	-6	0	N/A
3/31/2023	37	-6	-6	-1	N/A
12/31/2022	36	-6	-5	-1	N/A
9/30/2022	35	-6	-4	0	N/A
6/30/2022	33	-6	-3	1	N/A
3/31/2022	31	-3	-3	1	N/A
12/31/2021	30	-3	-2	2	N/A
9/30/2021	28	-2	-2	1	N/A
6/30/2021	26	-3	-2	1	N/A
3/31/2021	22	-6	-1	2	N/A
12/31/2020	23	-4	0	2	N/A
9/30/2020	25	-4	N/A	3	N/A
6/30/2020	27	-4	0	3	N/A
3/31/2020	31	-3	0	2	N/A
12/31/2019	32	-4	-1	2	N/A
9/30/2019	31	-3	0	2	N/A
6/30/2019	31	-3	2	3	N/A
3/31/2019	31	-3	1	3	N/A
12/31/2018	30	-4	1	3	N/A
9/30/2018	31	-9	2	4	N/A
6/30/2018	30	-22	1	2	N/A
3/31/2018	31	-21	N/A	3	N/A
12/31/2017	32	-22	N/A	4	N/A
9/30/2017	30	-18	N/A	4	N/A
6/30/2017	31	-6	N/A	4	N/A
3/31/2017	30	-4	N/A	3	N/A
12/31/2016	31	-3	N/A	0	N/A
9/30/2016	33	-3	N/A	-1	N/A
6/30/2016	33	-14	N/A	-3	N/A
3/31/2016	26	-22	N/A	-5	N/A
12/31/2015	18	-28	N/A	-7	N/A
9/30/2015	9	-34	N/A	-10	N/A
6/30/2015	1	-24	N/A	-12	N/A
3/31/2015	1	-15	N/A	-14	N/A
12/31/2014	1	-16	N/A	-18	N/A
9/30/2014	1	-14	N/A	-19	N/A
6/30/2014	1	-19	N/A	-20	N/A
3/31/2014	0	-27	N/A	-20	N/A
12/31/2013	1	-26	N/A	-19	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SSKN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SSKN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SSKN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SSKNの収益 ( 2.6% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: SSKNの収益 ( 2.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SSKNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

STRATA Skin Sciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 64%

Consensus EPS estimates fall by 33%

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Price target decreased by 11% to US$3.60

Consensus EPS estimates fall by 32%

Recent updates

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 29, 2024

Consensus estimates of losses per share improve by 64%

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

New minor risk - Shareholder dilution

STRATA Skin Sciences Announces Approval of XTRAC Momentum 1.0 Device in Japan

President recently bought US$60k worth of stock

STRATA Skin Sciences Regains Compliance with Nasdaq Rule 5550(a)(2)

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

STRATA Skin Sciences, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 11% to US$3.60

STRATA Skin Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Less than half of directors are independent

STRATA Skin Sciences, Inc. Announces Management Change

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 26, 2023

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast breakeven date moved forward to 2024

STRATA Skin Sciences, Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. Announces Board Changes

STRATA Skin Sciences, Inc. Announces First Patients Treated in TheraClear®X Clinical Study for Acne

First quarter 2023 earnings: EPS misses analyst expectations

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences Announces TheraClearX Product Demonstration at Inaugural Winter Clinical Conference

STRATA Skin Sciences, Inc. Revises Revenue Guidance for the Full Year 2022

STRATA Skin Sciences, Inc. Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Consensus estimates of losses per share improve by 12%

Forecast to breakeven in 2024

STRATA Skin Sciences, Inc. Reiterates Earnings Guidance for the Year 2022

STRATA Skin Sciences Receives Non-Compliance Letter from NASDAQ

STRATA Skin Sciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

STRATA Skin Sciences, Inc. Provides Revenue Guidance Full Year 2022

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

STRATA Skin Sciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Strata Skin Sciences Announces U.S. Commercial Launch of Theraclear®X Acne Therapy System

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

STRATA Skin Sciences, Inc., Annual General Meeting, Jun 22, 2022

Consensus forecasts updated

STRATA Skin Sciences, Inc. Names Michael E. Goodman as Head of International Sales

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

STRATA Skin Sciences, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$4.30

STRATA Skin Sciences, Inc. Appoints Patricia S. Walker to Its Board of Director

STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum 1.0 and First Installation in the U.S

STRATA Skin Sciences, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2021

Third quarter 2021 earnings released: US$0.015 loss per share (vs US$0.037 loss in 3Q 2020)

Price target increased to US$4.80

Independent Director recently bought US$104k worth of stock

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.05 loss in 2Q 2020)